{
  "id": 12849974,
  "title": "H.C. Wainwright downgrades Caribou Biosciences stock rating on halted programs",
  "url": "https://urgent.news/2026/10/08/h-c-wainwright-downgrades-caribou-biosciences-stock-rating-on-halted",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T11:02:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-downgrades-caribou-biosciences-stock-rating-on-halted-programs-93CH-4938503"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has lowered Caribou Biosciences Inc.'s stock rating to Neutral from Buy, and eliminated its price target. The downgrade comes after the biotech firm suspended all clinical programs. Caribou disclosed plans to explore strategic alternatives, with the goal of maximizing shareholder value and potentially exiting its two allogeneic CAR-T cell therapy programs. These discontinued programs include vispa-cel for treating relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma. The company plans to implement workforce and cost reductions, expected to conclude by the fourth quarter of 2026. The stock price has dropped 49% in a single week, falling to $0.62 and shrinking the company's market capitalization to $66.19 million. Caribou's financial situation appears concerning, as it is rapidly exhausting its cash reserves, despite having a solid current ratio of 6.49 and more cash than debt on its balance sheet. H.C. Wainwright's analyst Robert Burns revealed, \"Strategic alternatives are being explored as all clinical programs are halted.\" In related news, Caribou Biosciences announced significant changes in its development strategy, including the discontinuation of vispa-cel for B-cell lymphomas and CB-011 for multiple myeloma. Such moves have prompted analysts to reevaluate their ratings on Caribou Biosciences. Other firms, including RBC Capital and Leerink, have also downgraded the company, reflecting a cautiously negative outlook, given the strategic shift under way.",
  "summary": null,
  "key_points": [
    "H.C. Wainwright downgrades Caribou Biosciences stock rating to Neutral from Buy.",
    "Biotech firm suspends all clinical programs, including vispa-cel and CB-011.",
    "Company plans to explore strategic alternatives, reduce workforce and costs by Q4 2026."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}